Engflag

Vagibact

Quick links to important sections

Vagibact

Vagibact_ID

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vagibact

Property Description
Active ingredient Clindamycin and Clotrimazole
Form Vaginal Capsule, Suppository, or Cream
Pharmacological class Topical Anti-infective (Antibacterial and Antifungal)
General purpose Dual-pathogen targeting for microbial imbalance
Origin Semisynthetic (Clindamycin) and Synthetic (Clotrimazole)

Vagibact is defined as a Fixed Dose Combination (FDC) medicinal product, categorized broadly as a Topical Anti-infective Agent intended exclusively for intravaginal administration. This medicine typically comes in localized pharmaceutical preparations, such as a vaginal capsule, vaginal suppository (ovule), or vaginal cream, which facilitates the direct delivery of active components to the required site. This FDC classification establishes the drug's identity as a comprehensive agent, designed to administer two distinct pharmacological actions simultaneously, a therapeutic strategy widely employed when addressing conditions caused by mixed microbial populations.

Composition and Pharmacological Class

The core composition of Vagibact includes the two essential active ingredients: Clindamycin and Clotrimazole. Clindamycin is classified as a semisynthetic compound belonging to the lincosamide antibiotic class, which functions as a potent antibacterial agent. Clotrimazole, the second component, is an entirely synthetic compound categorized within the azole antifungals, acting as a broad-spectrum antimycotic agent. The combination of these specific agents is intended for use in scenarios where both bacterial and fungal organisms are present.

General Purpose of the Combination

The fundamental purpose of this dual combination is to provide dual-pathogen targeting against both bacterial and fungal microorganisms that commonly cause vaginal microbial imbalance. This strategy is employed to efficiently stop the growth and destroy these pathogens simultaneously. Clindamycin is used for its activity against bacterial imbalances. By addressing both potential microbial issues within a single preparation, Vagibact aims to promote the effective and comprehensive restoration of the local microbial environment.

Regulatory References

  1. MedlinePlus Clindamycin Information

What side effects are possible with Vagibact?

Vagibact, which contains clindamycin (an antibiotic) and clotrimazole (an antifungal), is generally well-tolerated when used vaginally, but it may cause localized and systemic side effects.

Common Localized Side Effects

The most frequent side effects are typically confined to the application area and may include:

  • Vaginal burning, stinging, or irritation
  • Vaginal itching or discomfort
  • Pain in the pelvic or lower abdominal area

These symptoms are often mild and may resolve as the treatment progresses. If irritation becomes severe or persists, it is important to contact a healthcare provider.

Systemic and Serious Side Effects

Because clindamycin is an antibiotic, there is a risk of systemic effects, including the development of Clostridioides difficile-associated diarrhea (CDAD), which can range from mild diarrhea to severe, life-threatening colitis. This may occur even weeks after the medication is stopped. Seek immediate medical attention if you experience severe abdominal cramps, persistent or watery diarrhea, or blood in your stool.

Rare, but serious, allergic reactions (anaphylaxis) have been reported with the components in Vagibact. Signs of a severe allergic reaction include a widespread rash, hives, swelling of the face, tongue, or throat, and difficulty breathing.

Contraindications and Safety Warnings

Do not use Vagibact if you have a history of hypersensitivity to clindamycin, lincomycin, clotrimazole, or any other component of the ovule. This medication is also contraindicated for individuals with a history of regional enteritis, ulcerative colitis, or antibiotic-associated colitis.

Interactions with Contraceptives: The inactive ingredients in Vagibact can weaken latex or rubber products, such as condoms and vaginal diaphragms. The reliability of these contraceptive methods may be compromised during treatment and for at least 72 hours (three days) after the last dose.

Overdose and Emergency Response

The official regulatory documents define the overdose profile of this vaginal product primarily through the potential for systemic exposure to the Clindamycin component. Even with localized administration, sufficient absorption may occur to produce systemic effects, which carries the documented, severe risk of developing pseudomembranous colitis. Manifestations of this serious complication include severe bloody or watery diarrhea, abdominal pain, nausea, fever, and vomiting. If the product is accidentally swallowed, specific symptoms such as dizziness, nausea, or vomiting may also be documented.

In the event of a suspected overdose, the official regulatory guidance is to seek immediate medical attention. Urgent medical help is explicitly required for any severe systemic symptoms. Individuals must call emergency services (such as 911) immediately if the affected person shows signs of collapse, experiences a seizure, has trouble breathing, or cannot be awakened. Contacting a Poison Control Center or a hospital emergency department is also mandated as an immediate action. Regulatory information confirms that no specific antidote is known for the active components. Consequently, the official management approach is limited to general symptomatic and supportive treatment.

Therapeutic Uses of Vagibact

The Clindamycin and Clotrimazole combination is relevant in contexts marked by increased discomfort or tension caused by infective vaginal imbalance, specifically addressing scenarios where multiple types of organisms create noticeable physiological strain. This combination is generally relevant for gynecological infections presenting with symptomatic discomfort linked to bacterial and fungal activity.

Managing Symptoms of Mixed Bacterial and Fungal Infections

This combination is commonly used across conditions presenting with acute episodes where symptomatic discomfort is linked to mixed infection, involving both pathogenic bacteria (associated with Bacterial Vaginosis) and fungal organisms (associated with Vulvovaginal Candidiasis). The therapeutic approach is focused on managing dual-pathogen related symptoms, which supports the overall management of mixed vaginosis and assists in addressing the vaginal microbial imbalance. This treatment is applied in clinical settings that involve acute or unstable symptom patterns.

Alleviating Discomfort, Itching, and Foul Odor

The therapy may assist with managing symptoms that interfere with daily comfort, including inflammatory or irritative states such as vaginal and vulvar itching, a burning sensation, and associated irritation that may become disruptive. Crucially, it is applied in addressing the infective discharge complex and contributes to easing the symptom load associated with abnormal discharge consistency and the characteristic foul or fish-like odor linked to bacterial overgrowth. This contributes to improved comfort during periods of heightened symptoms and assists with maintaining functional stability.

Quick Fact: Relief for Infective Discomfort

This combination treatment is generally relevant for easing the acute, pronounced symptoms of infective vaginitis, including itching, burning, and foul odor that may become pronounced, and contributes to easing the overall symptom burden.

Eligibility and Restrictions for Use

The eligibility profile for Vagibact (Clotrimazole) Cream is based on official government regulatory documents, which define specific populations for whom use is allowed, restricted, or strictly prohibited.

Populations for Whom Use is Contraindicated

Use of Vagibact is strictly contraindicated for individuals with a known hypersensitivity or allergic reaction to the active substance, clotrimazole, or any of the product's inactive ingredients (excipients).

Age-Related Eligibility

The product is generally indicated for use in adults and adolescents aged 12 years and older. Use in children under 12 years for vaginal application is typically not established or requires consultation with a healthcare provider.

Use During Pregnancy and Breastfeeding

While systemic absorption is minimal, use during pregnancy (especially the first trimester) is generally advised under the supervision of a physician. Use during lactation (breastfeeding) is generally permitted, though the patient should exercise caution.

Eligibility-Related Restrictions

Patients must be advised that the cream's components may damage and reduce the effectiveness of latex contraceptive devices (condoms and diaphragms). Alternative contraceptive methods must be used during and for a specified time after treatment. The product is not intended for ophthalmic use (in the eyes).

What should I know about interactions with other medicines?

This section describes the officially documented interaction patterns for the active ingredients Clindamycin and Clotrimazole as stated in government regulatory sources, strictly adhering to the prescriptive information.

Official Interaction Profile

Interacting Substance/Product Interaction Classification Official Description of Outcome
Oral Tacrolimus, Oral Sirolimus Pharmacokinetic (Exposure Modification) Co-administration may lead to increased plasma levels of these immunosuppressants.
Neuromuscular Blocking Agents Pharmacodynamic (Enhancement) Clindamycin has properties that may enhance the action of these co-administered agents.
Latex/Rubber Barrier Contraceptives Functional/Physical Incompatibility The vaginal formulation base may weaken the material, requiring a mandatory timing constraint.

Regulatory Constraints and Timing Rules

The official labeling establishes two key types of constraints based on documented interaction risks. The first is a functional incompatibility: due to the oleaginous excipients in the vaginal formulation, a physical interaction is documented where the product may weaken devices made of latex or rubber. Regulatory documents require that the use of these barrier contraceptives (condoms, diaphragms) be not recommended concurrently or for a specified time period ranging from 72 hours up to five days following the completion of treatment. The second constraint involves a risk of exposure modification: the Clotrimazole component may increase the systemic exposure of co-administered oral immunosuppressants. These documented interactions and constraints constitute the complete non-interpretive regulatory profile.

Mechanism of Action

Targeting the Essential Microbial Machinery

Vagibact functions as a protein synthesis inhibitor by selectively targeting the 50S ribosomal subunit within susceptible microorganisms. The active compound forms a stable bond with this subunit, which is the cellular complex responsible for manufacturing essential proteins. This critical interaction immediately interrupts the translation phase, specifically blocking the elongation of peptide chains. This mechanistic action is required to interrupt the fundamental life processes of the target organisms.

Inhibiting Microbial Replication and Growth

The resulting molecular disruption prevents the microorganisms from creating the structural components and enzymatic proteins needed for survival and cell division. This cascade leads to a suppression of the target microbial population, which is the resulting physiological effect of the mechanism. The reduction in the population of susceptible organisms is the process that allows for the restoration of the local microbial population balance in the application environment.

Dosage and Administration Information

The use of the Clindamycin and Clotrimazole fixed-dose combination (FDC) is structured around standardized administration guidelines intended for a localized effect. This medicine is strictly for intravaginal administration and must not be used by the oral, dermal, or ophthalmic routes. The usage pattern is defined by a short-term, fixed dosing schedule over a specific number of consecutive nights.

Official Administration Protocol

Principle of Use General Guidelines
Dosing Unit and Frequency The standard regimen is one unit (suppository or capsule) administered once daily.
Course Duration The treatment is a short, defined course lasting either 3 consecutive nights or 7 consecutive nights, depending on the specific formulation's labeling.
Timing The administration must be completed at bedtime (before sleep). This timing is crucial to ensure the dose remains retained at the site of application for the required duration.

Specific Usage Contexts

Patients are generally directed to insert the unit deeply into the vagina while lying in a recumbent position. During the entire course of treatment, the use of other intravaginal products, such as tampons or douches, is generally discouraged. The instructions define the product's base as potentially compromising the integrity of latex or rubber barrier contraceptives, necessitating a related use restriction. Regarding population, the use of this treatment is generally established in post-menarchal females. If a scheduled dose is missed, instructions advise applying it as soon as remembered, but strictly prohibit taking double doses to make up for a skipped application.

Recent Clinical Evidence

Evidence for use in Mixed Vaginosis (Bacterial and Fungal Origin)

This medicine was studied for conditions involving the simultaneous presence of both bacterial and fungal organisms, a situation referred to as mixed vaginosis. Research examined this combination treatment in adult women who presented with symptomatic discomfort and received a clinical diagnosis of this microbial imbalance. These investigations typically involved multi-center prospective studies, meaning researchers monitored outcomes in groups of patients over defined time intervals. The findings describe patterns observed in the studies related to measured outcomes. Research highlights changes measured during the study period, such as the normalization of vaginal pH status and the measured state of vaginal discharge characteristics. Studies monitored how symptoms evolved in the observed populations, and the data show patterns related to the observed short-term symptomatic status, which were tracked by both physicians and the patients themselves. This evidence contributes to understanding symptom patterns in conditions associated with acute or disruptive episodes.

Study Designs and Assessed Outcomes

The research available largely includes open-label and non-comparative clinical experience evaluations. This means that the medicine was not directly compared against an inactive substance or against other existing treatments within the same study. The study outcomes examined focused heavily on patient-reported outcomes describing perceived discomfort and physical discomfort, such as vaginal burning and irritation. Studies monitored how symptoms evolved in the observed populations, with a focus on endpoints related to clinical resolution—meaning the absence of signs of infection—which was generally assessed within a defined follow-up period. The collected data provide context but not individual predictions about patient response, as study results reflect the specific conditions under which they were conducted.

Long-Term Follow-up and Durability of Response

Clinical research for this medicine focused mainly on the short-term response to the treatment. The typical follow-up durations were short-term, with primary assessments commonly ranging from three to seven days after treatment initiation. Data are still emerging, and certainty remains low regarding sustained outcomes. There is limited information for long-term outcomes, meaning that the full picture of how symptoms behave months after treatment and the frequency of recurrence are not well characterized in the main published research. The evidence contributes to understanding the short-term status of symptoms, but monitoring was focused on the initial short-term period.

Evidence in Specific Study Populations

The research examined this combination primarily in symptomatic adult women who met specific diagnostic criteria for infective vaginitis. Studies monitored patients aged 18 years and older with conditions marked by functional limitations and periods of heightened symptoms. Findings describe group patterns related to these specific populations.

However, data for certain groups remain insufficient. Follow-up durations were short-term, and studies did not extensively evaluate outcomes in specific subgroups, such as pregnant women, post-menopausal women, or patients with certain chronic co-existing medical conditions. Therefore, results apply only to the populations studied, and the evidence quality varies across these potentially excluded groups.

Research Gaps and Areas for Further Study

The existing research provides insight into short-term changes. However, key research gaps remain. The evidence quality varies across studies, with many utilizing designs that were open-label and non-comparative, which limits the ability to draw firm conclusions about the certainty of the findings. Comparative evidence is lacking to explore how this fixed-dose combination compares when measured head-to-head against single-ingredient treatments or other treatment strategies. Furthermore, long-term outcomes are not fully established. Research is ongoing, but the data available for the durability of the reported changes and the frequency of recurrence are still emerging.

Key Studies & References

  1. A Clinical Experience to Assess Safety and Efficacy of Fixed Dose Combination of Clindamycin and Clotrimazole in the Treatment of Patients With Mixed Bacterial and Fungal Vaginosis

Frequently Asked Questions (FAQ)

Common questions about Vagibact (FAQ)

Q: Are there different strengths or versions of Vagibact?

Official labeling indicates that Vagibact is available in different formulations, such as a vaginal capsule or cream. These products may be packaged for either a 3-day or a 7-day course of treatment. Official product information describes these differences in form and duration but does not provide specific details on varying strengths of the active ingredients between these products.

Q: Can I use Vagibact if I am allergic to similar types of medications?

Official regulatory documents list strict contraindications for individuals with a known hypersensitivity to the medicine's active ingredients (clindamycin, lincomycin, clotrimazole) or any of its inactive components. If you have an allergy to medications chemically similar to these, professional consultation is generally recommended to review this medical history before use.

Q: Can men use Vagibact for any condition?

Regulatory and official product information states that Vagibact is specifically indicated for use in post-menarchal and adult females to treat infective vaginitis. The official documents do not describe or provide guidance for the product's use in men for any condition.

Q: Does Vagibact contain any preservatives or inactive ingredients I should know about?

Official product labeling must list all ingredients, including excipients (inactive ingredients). Specific excipients listed include substances like propylene glycol, cetostearyl alcohol, and benzyl alcohol. Regulatory information notes that some of these inactive components may potentially cause localized skin reactions.

Q: Can I use Vagibact while also using a topical antifungal cream?

Regulatory guidance advises that patients should generally avoid using other vaginal products concurrently with Vagibact to ensure treatment effectiveness. If you are considering using a co-administered topical cream, consultation with a healthcare provider is suggested to evaluate concurrent product use.

Q: Is Vagibact indicated for recurrent episodes?

Research evidence for the durability of response following Vagibact treatment is still emerging, with limited information available on long-term outcomes. Official guidance on the clotrimazole component suggests that if the infection returns in less than two months, professional medical review is warranted.

Q: Is it normal to see some discharge after using Vagibact?

Regulatory data for the clindamycin component of Vagibact lists a change in the color, amount, or odor of vaginal discharge as a possible side effect. If you notice unusual or severe discharge, this may be related to the medicine.

Q: Can Vagibact affect my period or cycle?

Official patient information states that use of the medicine is generally intended to continue without interruption even if a menstrual period begins during the time of treatment, to facilitate the full course completion. This condition is part of the established administration protocol.

Q: Is Vagibact available over the counter and does it require a prescription?

According to official drug listings and regulatory status, Vagibact is classified as a Prescription-Only Medicine (POM). This means the medicine requires a valid prescription from a licensed healthcare provider before it can be dispensed.

Q: Does Vagibact affect the use of hormonal birth control?

Official regulatory warnings related to the clindamycin component suggest that antibiotics may potentially reduce the effectiveness of hormonal contraceptives that contain ethinyl estradiol (a common estrogen in birth control pills). This could be associated with an increased risk of pregnancy.

Q: Is Vagibact safe to use if I have an IUD?

Regulatory sources indicate that the localized action of most vaginal antibiotics and antifungals generally does not affect the functionality of intrauterine devices (IUDs). However, because different types of IUDs exist (hormonal or non-hormonal), any concerns about concurrent use require professional medical review.

Q: Why do some people experience yeast infections after using Vagibact?

Official side effect lists for the clindamycin component note vaginal thrush (a yeast infection) as a possible common side effect. This is a common phenomenon that can occur when the antibiotic component alters the natural microbial balance in the vagina.

Q: What happens if Vagibact is accidentally swallowed?

Regulatory safety guidance states that Vagibact is strictly intended for intravaginal administration and must not be swallowed. Regulatory safety guidance requires that if this medicine is accidentally ingested, a doctor or poison control center be contacted right away.

Q: Is Vagibact treatment known to cause any odor issues?

Official regulatory data for the clindamycin component of Vagibact lists a bad-smelling vaginal discharge or a change in the odor of vaginal discharge as a possible side effect. This is noted as a possibility for clindamycin vaginal products.

Q: Is Vagibact known to cause headaches?

Official side effect lists for the vaginal cream formulation of the medicine's components include headache as a possible common side effect.

Q: What is the shelf life of Vagibact?

Official storage instructions focus on how to store the medicine, advising to keep it tightly closed and protected from light and humidity. Regulatory guidance requires that outdated or expired medicine not be used, but generally does not specify a shelf-life duration in the patient information.

Q: Is it necessary to complete the full course of Vagibact even if symptoms improve quickly?

Official patient information states that treatment is generally not intended to be stopped even if symptoms improve quickly. Completion of the entire course of treatment is required by the prescribing instructions to address the infection fully.

Q: Does Vagibact have a known impact on sexual partners?

Official regulatory guidance notes that the oleaginous excipients in the medicine can weaken latex barrier contraceptives, impacting protection for sexual partners. Additionally, guidance on the clotrimazole component addresses partner involvement and the possibility of external treatment to manage re-infection.

Q: Does Vagibact have a black box warning?

The systemic (oral) version of the antibiotic component, clindamycin, carries an FDA Boxed Warning regarding the risk of Clostridioides difficile-associated diarrhea (CDAD). This serious risk is also cautioned about for the vaginal formulation due to potential, though minimal, systemic absorption.

How should Vagibact be stored and disposed of?

How to Store and Dispose of Vagibact

Vagibact (Clindamycin/Clotrimazole FDC) must be stored according to specific regulatory conditions to maintain its stability and effectiveness.

Storage Requirements

Condition Requirement
Temperature Store at controlled room temperature (typically below 30 C / 86 F).
Protection Keep in the original, tightly closed container and protect from light and high humidity.
Prohibited The product must not be frozen and must be kept away from excessive heat.
Child Safety Store the medication out of sight and reach of children and pets.

Disposal Instructions

Unused or expired medication must be handled according to local regulatory guidelines. The product must not be disposed of by flushing down the toilet or pouring into a drain (wastewater). Follow the instructions from a healthcare professional or local authority on how to safely discard the medicine and any used application devices.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Vagibact found in:

A-Z Index: